Search Results
10
Everything
Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference
March 24, 2025 06:59 ET
|
Pasithea
Pasithea Therapeutics (KTTA) will present PAS-004 Phase 1 data at the 2025 CAGLA NeauxCancer Conference on March 28 in New Orleans.
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
February 05, 2025 06:59 ET
|
Pasithea
Pasithea's PAS-004 Phase 1 trial advances to 22mg dose with no DLTs or rash, reinforcing its safety profile as a next-gen MEK inhibitor for NF1 and cancer.
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
January 14, 2025 08:02 ET
|
Pasithea
Pasithea opens EU trial sites for PAS-004, doses Cohort 4, and plans interim safety data in Q1 2025.
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
November 20, 2024 07:02 ET
|
Pasithea
Pasithea Tx' PAS-004 Phase 1 trial advances to a 15mg dose after no toxicities or rash observed, highlighting its safety and differentiated profile.
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
September 09, 2024 08:01 ET
|
Pasithea
Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
September 03, 2024 08:02 ET
|
Pasithea
Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004.
Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024 09:11 ET
|
Pasithea
Pasithea Therapeutics will present at H.C. Wainwright’s Global Investment Conference, highlighting PAS-004 development for NF1 and cancer.
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
May 28, 2024 06:59 ET
|
Pasithea
Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
April 24, 2024 07:59 ET
|
Pasithea
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
February 13, 2024 07:59 ET
|
Pasithea
Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data.